Webinar · Palm Beach, Florida

Orphan Drugs: the Conundrum- Clinical Research Trials

Education, Training

Official website
Next editionNot confirmedLast edition we have: 19 Aug 2015
Last venueOnlineWebinar
RunningSince 2015Frequency unknown · 1 edition on record
Last checked12 Nov 2026Organiser website checked
We haven't confirmed the next dates yet. The last edition in our records was 19 Aug 2015 at Webinar Venue. Check the organiser's site: onlinecompliancepanel.com. Are you the organiser? Correct this listing.

Key numbers

Editions on record
1first in 2015

About Orphan Drugs: the Conundrum- Clinical Research Trials

Orphan Drugs: The ConundrumOrphan Drugs Instructor: Dr Marybeth Regan Product ID: 500903 Level: Intermediate Description The Orphan Drug Act is intended to treat conditions affecting less than 200,000 patients in the US – about 1 in 1500 people. These cases are where there is no reasonable expectation that the developer will recover the costs of drug development and marketing via future sales of the drug in the US. The areas covered in this webinar are: Definition of the Orphan Drug Act Role of the FDA Understanding why the Orphan Drug Act has started a conundrum Why the varying views Good Intentions, Bad Results Competing in the Rare Disease Space Review of drugs passed that are Orphan Drugs Comparison of Rare Disease Drugs VS other drugs Benefits of the Orphan Drug Act VS drawbacks Why Should you Attend: The Orphan Drug Act was approved in 1983. The question that remains is whether the FDA is encouraging pharmaceutical companies to use its resources in the most efficient manner. According to Clinical Leader Magazine, there are approximately 7,000 different types of rare diseases and disorders affecting an estimated 350 million people worldwide. These diseases are different in many ways and there are the variations in patient treatment and gaps in care. The Rare Disease Impact Report mentions that it takes an average of seven years for a patient with a rare disease in the United States to receive a proper diagnosis. Between diagnosis and treatment, a patient typically visits up to eight different physicians and receives two to three misdiagnoses. Objectives of the Presentation: Understanding the objective of the Orphan Drug Act Understanding why the Orphan Drug Act has started a conundrum What is the role of the FDA as it pertains to Orphan Drugs? History of the results of the Orphan Drug Act What is the likeliest future? Who can Benefit: Benefit Managers Director of Human Resource Director of Access Director of Strategy Pharmacy Benefit Managers Representatives of

From our listing of this edition. Details may have changed since.

Editions

YearDatesWhereExhibitorsVisitors
201519 Aug 2015Webinar Venue
Online
——

Past editions from the bvents archive (2008–2019) and organiser figures where they were published.

Questions

When is Orphan Drugs: the Conundrum- Clinical Research Trials?

The next dates haven't been confirmed. The last edition we have on record was 19 Aug 2015.

Where is it held?

The last edition we have was at Webinar Venue, Palm Beach, Florida.

Who organises it?

ComplianceOnline.

Industries